|  |
| --- |
| Supplementary table 1. Acquired drug resistance mutations among female sex workers with virologic failure (n=29) |
| Participant | Age | CD4+ T cell count (cells/mm3) | HIV-1 RNA load (copies/mL) | NRTI HIVDR mutations | NNRTI HIVDR mutations | High level resistance NRTI  | High level resistance NNRTI  |
| ETH\_\_1588 | 35 | 349 | 147448 | M184V, T215F | K103N, E138A, H221Y, M230L | FTC, 3TC | DOR, EFV, NVP, RPV |
| ETH\_\_1621 | 21 | 39 | 1662073 | A62AV, K65R, Y115YF, M184V | L100I, K103N | ABC, FTC,3TC, TDF | EFV, NVP, RPV |
| ETH\_\_1622 | 19 | 433 | 1412 | None | V106M, G190A | None | EFV, NVP |
| ETH\_\_1627 | 30 | 379 | 16014 | K70KR, M184V | K101E, V106M, G190A | FTC,3TC | DOR, EFV, NVP, RPV |
| ETH\_\_1630 | 26 | 419 | 1662 | None | G190A | None | NVP |
| ETH\_\_1631 | 25 | 1348 | 1288 | M184V | K103N | FTC,3TC | EFV, NVP |
| ETH\_\_1645 | 30 | 24 | 93357 | None | K101P, K103N | None | EFV, ETR, NVP, RPV |
| ETH\_\_1652 | 30 | 436 | 77253 | K70KR, M184V | K103N, Y181C, H221Y | FTC,3TC | EFV, NVP, RPV |
| ETH\_\_1666 | 35 | 420 | 107231 | M184V | K103N, H221HY | FTC,3TC | EFV, NVP |
| ETH\_\_1712 | 30 | 157 | 424627 | K65R | K103N, Y181C, H221HY, P225PH | D4T, TDF | DOR, EFV, NVP, RPV |
| ETH\_\_1724 | 40 | 681 | 3569 | M184V, K219KE | K103NS, G190A | FTC,3TC | EFV, NVP |
| ETH\_\_1726 | 45 | 544 | 28716 | None | K103N | None | NVP, EFV |
| ETH\_\_1727 | 45 | 163 | 45715 | None | V106VM | None | EFV, NVP |
| ETH\_\_1730 | 27 | 289 | 8598 | M184V | A98AG, Y181V, H221HY | FTC,3TC | DOR, ETR, NVP, RPV |
| ETH\_\_1736 | 36 | 201 | 95220 | None | G190A | None | NVP |
| ETH\_\_1753 | 20 | \*\* | 22343 | A62AV, K65R | K103N, V179F, Y181C, H221HY | TDF | EFV, ETR, NVP, EFV |
| ETH\_\_1779 | 30 | 126 | 16332 | M184V, T215Y | K101E, E138A, G190A | FTC,3TC | EFV, NVP, RPV |
| ETH\_\_1780 | 30 | 72 | 302382 | D67N, K70R, M184V, T215I, K219E | A98G, K103N, V108I, Y181C, K238T | ABC, D4T, FTC,3TC, AZT | DOR, EFV, NVP, RPV |
| ETH\_\_1786 | 30 | 258 | 114301 | D67N, K70R, M184V, T215TA, K219EQ | K101E, G190A, P225H | ABC, D4T, FTC,3TC, AZT | EFV, NVP, RPV |
| ETH\_\_1787 | 35 | 718 | 12911 | K65KR | A98G, K103N, Y181C | D4T, TDF | EFV, NVP, RPV |
| ETH\_\_1856 | 25 | 175 | 1706 | K70R, M184V, K219Q | A98G,100LI, V106M, Y181C, F227FL | FTC,3TC | DOR, EFV, ETR, NVP, RPV |
| ETH\_\_1857 | 38 | 97 | 197807 | K65R, L74I, Y115F, M184V | L100I, K103N | ABC, FTC,3TC, TDF | EFV, NVP, RPV |
| ETH\_\_1870 | 28 | 581 | 8175 | M41L, M184V, T215F | V179D, Y181C | FTC,3TC | EFV, NVP, RPV |
| ETH\_\_1873 | 28 | 212 | 82465 | M184MV | K101KE, K103N | FTC,3TC | EFV, NVP |
| ETH\_\_1884 | 35 | 630 | 4944 | M184V | K103N, V108VI | FTC,3TC | EFV, NVP |
| ETH\_\_1910 | 31 | 623 | 1280 | M184V | K103N, V108I | FTC,3TC | EFV, NVP |
| ETH\_\_1962 | 30 | 336 | 1153 | A62V, K65R, Y115F, M184V | Y181C | ABC, FTC,3TC, TDF | NVP |
| ETH\_\_1985 | 27 | 164 | 12995 | K70E, M184V | A98G, K103N, Y181C | FTC,3TC | EFV, NVP, RPV |
| ETH\_\_1993 | 35 | 576 | 1199 | M184V | K103N, V108VI | FTC,3TC | EFV, NVP |

High-level resistance (mutation net drug score of ≥60)

\*\*CD4 T-cell count was not recorded.

Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; ABC, abacavir; AZT, zidovudine; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir; D4T, stavudine; NNRTI, non-nucleoside reverse transcriptase inhibitor; DOR, doravirine; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine